Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (14)

2024

  1. Expanding the Spectrum of Skin Neoplasms in Muir-Torre Syndrome: Beyond Sebaceous Tumours

    American Journal of Dermatopathology

2018

  1. A survey of perceptions, attitudes, knowledge and practices of medical oncologists about cancer pain management in Spain

    Clinical and Translational Oncology, Vol. 20, Núm. 8, pp. 1061-1071

  2. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

    Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 862-869

2017

  1. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study

    International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 3, pp. 473-480

2016

  1. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients with Unresectable Squamous Cell Carcinoma of the Head and Neck

    International Journal of Radiation Oncology Biology Physics, Vol. 94, Núm. 2, pp. 289-296

  2. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study

    Oral Oncology, Vol. 62, pp. 54-59

2014

  1. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer

    Annals of Oncology, Vol. 25, Núm. 1, pp. 216-225

  2. Análisis de impacto presupuestario del uso de fentanilo intranasal en pectina para el tratamiento del dolor irruptivo oncológico

    Pharmacoeconomics - Spanish Research Articles, Vol. 11, Núm. 2, pp. 51-60

2013

  1. Optimal management of breakthrough cancer pain (BCP)

    Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 526-534

  2. Relationship between the pharmacokinetic properties and efficacy of fentanyl pectin nasal spray in breakthrough cancer pain

    Atencion Farmaceutica, Vol. 15, Núm. 1, pp. 40-45

2012

  1. Breakthrough cancer pain - Still a challenge

    Journal of Pain Research, Vol. 5, pp. 559-566

  2. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

    Annals of Oncology, Vol. 23, Núm. 4, pp. 1016-1022

2010

  1. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

    British Journal of Cancer, Vol. 102, Núm. 12, pp. 1687-1691

2005

  1. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer

    Investigational New Drugs, Vol. 23, Núm. 3, pp. 243-251